

Introduction to ACIP's Combination Vaccine Work Group

Kelly Moore, MD, MPH

Chair, Combination Vaccines Work Group

Advisory Committee on Immunization Practices

June 26, 2019

Work Group Members

ACIP Members

- Kelly Moore (Chair)
- Veronica McNally

***Ex Officio* Members**

- Ann Schwartz (FDA)
- Jillian Doss-Walker (IHS)
- Tom Weiser (IHS)

Liaison Representatives

- Sarah McQueen (AAPA)
- Jennifer Hamilton (AAFP)
- Patsy Stinchfield (NAPNAP)
- Sean O’Leary (AAP)
- Elizabeth Rausch-Phung (AIM)
- Phil Griffin (AIM)

CDC Contributors

- Sara Oliver (CDC Work Group Lead, *Haemophilus influenzae* SME)
- Fiona Havers (Pertussis SME)
- Anna Acosta (Diphtheria/Tetanus SME)
- Janell Routh (Polio SME)
- Sarah Schillie (Hepatitis SME)
- Tamara Pilishvili (*Streptococcus pneumoniae* SME)
- Cindy Weinbaum (Immunization Services Division)
- JoEllen Wolicki (Immunization Services Division)
- Pedro Moro (Immunization Safety Office)
- Mike Bruce (AI/AN SME)
- Rosalyn Singleton (AI/AN SME)

Pediatric hexavalent vaccine

- Joint venture between Merck and Sanofi Pasteur
 - Diphtheria, tetanus, pertussis (DTaP5)
 - Polio (IPV)
 - *Haemophilus influenzae* type b (Hib; PRP-OMP)
 - Hepatitis B (Hep B)
- Official abbreviation: DTaP-IPV-Hib-HepB
- Given in a 3-dose series (2, 4, 6 months)
- Approved and licensed by the FDA on December 21, 2018
- Manufacturer has stated vaccine not commercially available prior to 2021

Topics Under Consideration

- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be preferentially recommended for the American Indian/Alaska Native (AI/AN) population
- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be included as an option in the Vaccines for Children (VFC) Program for the infant series at 2, 4, and 6 months of age

Topics Under Consideration

- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be preferentially recommended for the American Indian/Alaskan Native (AI/AN) population
 - Preferential recommendation would require ACIP vote
- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be included as an option in the Vaccines for Children (VFC) Program for the infant series at 2, 4, and 6 months of age
 - Requires only a VFC vote

February ACIP Presentations

- Immunogenicity and Safety of Pediatric Hexavalent Vaccine
 - Andrew Lee, Merck
- Hib Epidemiology and Vaccines in American Indian/Alaska Native Population
 - Laura Hammitt, Center for American Indian Health, Johns Hopkins
- Summary, Review of Work Group Considerations
 - Sara Oliver, CDC/NCIRD

Work Group Activities

- Work Group Calls
 - Reviewed safety and immunogenicity data
 - Reviewed Hib epidemiology and Hib vaccines among AI/AN population
 - Reviewed use of combination vaccines in infant series
 - Discussed policy options
- 2019: Publication of MMWR Policy Note

Agenda

- Summary and Relevant Evidence to Recommendations Framework
 - Sara Oliver, CDC/NCIRD

- VFC votes
 - Jeanne Santoli, CDC/NCIRD

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

